Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Virology

• Publication date

  2004-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.78.7.3572-3577.2004PMID 15016880PMCID PMC371090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

  2003cited by this paper
• Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong

  2003cited by this paper
• Aetiology: Koch's postulates fulfilled for SARS virus

  2003cited by this paper
• Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China

  2003cited by this paper
• Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

  2003cited by this paper
• Critically ill patients with severe acute respiratory syndrome.

  2003cited by this paper
• Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

  2003cited by this paper
• SARS coronavirus: a new challenge for prevention and therapy.

  2003cited by this paper
• Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

  2003cited by this paper
• SARS virus infection of cats and ferrets

  2003cited by this paper
• Identification of severe acute respiratory syndrome in Canada.

  2003cited by this paper
• Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

  2003cited by this paper
• A major outbreak of severe acute respiratory syndrome in Hong Kong.

  2003cited by this paper
• A novel coronavirus associated with severe acute respiratory syndrome.

  2003cited by this paper
• Activity of Polymerase Proteins of Vaccine and Wild-Type Measles Virus Strains in a Minigenome Replication Assay

  2002cited by this paper
• Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever

  2002cited by this paper
• Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model.

  2000cited by this paper
• Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

  2000cited by this paper
• Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice.

  1997cited by this paper
• Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis.

  1997cited by this paper
• Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.

  1994cited by this paper
• 29 – Mucosal Immunity to Viruses

  1994cited by this paper
• Murine model for evaluation of protective immunity to influenza virus.

  1993cited by this paper
• A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination

  1993cited by this paper
• Influenza virus infections and immunity: a review of human and animal models.

  1992cited by this paper
• INFLUENZA VIRUS INFECTIONS AND IMMUNITY : A REVIEW OF HUMAN AND ANIMAL MODELS

  1992cited by this paper
• Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

  1990cited by this paper
• Primary respiratory syncytial virus infection in mice

  1988cited by this paper
• Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

  1985cited by this paper
• Pathogenesis of Feline Infectious Peritonitis: Pathologic Changes and Immunofluorescence

  1981cited by this paper
• Pathogenesis of feline infetious peritonitis: pathologic changes and immunofluorescence.

  1981cited by this paper
• Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia.

  1981cited by this paper
• Pathogenesis of feline infectious peritonitis: nature and development of viremia.

  1981cited by this paper
• Immunologic phenomena in the effusive form of feline infectious peritonitis.

  1980cited by this paper
• Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis

  1979cited by this paper
• Effects of Low- and High-Passage Influenza Virus Infection in Normal and Nude Mice

  1977cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2

  2025cites this paper
• Animal Models for Human-Pathogenic Coronavirus and Animal Coronavirus Research

  2025cites this paper
• Constructions and immunogenicity evaluations of two porcine epdemic diarrhea virus-like particle vaccines.

  2025cites this paper
• Ontology-based taxonomical analysis of experimentally verified natural and laboratory human coronavirus hosts and its implication for COVID-19 virus origination and transmission

  2024cites this paper
• Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection

  2024cites this paper
• Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus

  2024cites this paper
• Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection

  2024cites this paper
• Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms

  2023cites this paper
• Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters

  2023cites this paper
• Taxonomical and ontological analysis of verified natural and laboratory human coronavirus hosts

  2023cites this paper
• Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus

  2023cites this paper
• Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women

  2023cites this paper
• Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19

  2023cites this paper
• Correlation of viral loads in disease transmission could affect early estimates of the reproduction number

  2023cites this paper
• ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus

  2023cites this paper
• Olfactory immunology: the missing piece in airway and CNS defence

  2023cites this paper
• Mucosal plasma cells are required to protect the upper airway and brain from infection.

  2022cites this paper
• Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets

  2022cites this paper
• Animal models for studying coronavirus infections and developing antiviral agents and vaccines

  2022cites this paper
• Potential intestinal infection and faecal‐oral transmission of human coronaviruses

  2022cites this paper
• Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations

  2022cites this paper
• Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants

  2022influential citation
• Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys

  2022cites this paper
• Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2

  2022cites this paper
• Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2

  2022influential citation
• Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques

  2022cites this paper
• Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters

  2022cites this paper
• Correlation of viral loads in disease transmission chains could bias early estimates of the reproduction number

  2022influential citation
• Central Nervous System: human brain normal glial and glioma

  2022cites this paper
• Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches

  2022cites this paper
• Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants

  2022cites this paper
• Animal Models of COVID-19: Transgenic Mouse Model.

  2022cites this paper
• Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2

  2022cites this paper
• Visualizing a Field of Research for the Coronavirus Replication in Humans with Knowledge Mapping: Evidence from Web of Science

  2022cites this paper
• Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2

  2021cites this paper
• Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques

  2021cites this paper
• LDH nanoparticle adjuvant subunit vaccine induces an effective immune response for porcine epidemic diarrhea virus.

  2021cites this paper
• Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

  2021cites this paper
• Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain

  2021cites this paper
• A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

  2021cites this paper
• Systems serology detects functionally distinct coronavirus antibody features in children and elderly

  2021cites this paper
• Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis

  2021cites this paper
• Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43

  2021cites this paper
• Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

  2021influential citation
• Title: 1 Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants 2 with a novel competitive multiplex assay. 3

  2021cites this paper
• Current advances in the development of SARS-CoV-2 vaccines

  2021cites this paper
• Title: 1 Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants 2 with a novel competitive multiplex assay. 3

  2021cites this paper
• Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection

  2021cites this paper
• Title: 1 Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants 2 with a novel competitive multiplex assay. 3

  2021cites this paper
• Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

  2021cites this paper
• Passive Immunity Should and Will Work for COVID-19 for Some Patients

  2021cites this paper
• Evaluation of six commercial SARS-CoV-2 Enzyme-Linked Immunosorbent assays for clinical testing and serosurveillance

  2021cites this paper
• Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma

  2021cites this paper
• Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia

  2021cites this paper
• Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

  2021cites this paper
• An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms

  2021cites this paper
• Generation and Characterization of a Nanobody Against SARS-CoV

  2021cites this paper
• Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

  2021cites this paper
• D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-α/NF-κB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis

  2021cites this paper
• Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

  2021cites this paper
• Anthropogenic Infection of Cats during the 2020 COVID-19 Pandemic

  2021cites this paper
• Drug repurposing for COVID-19: Approaches, challenges and promising candidates

  2021cites this paper
• Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

  2021cites this paper
• Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19

  2021cites this paper
• Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance

  2021cites this paper
• DISAPPEARANCE OF ANTIBODIES IN COVID-19 MYTHS ORREALITY

  2021cites this paper
• Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity

  2021cites this paper
• The success of SARS-CoV-2 vaccines and challenges ahead

  2021cites this paper
• A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters

  2021cites this paper
• Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

  2021cites this paper
• Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay

  2021cites this paper
• The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)

  2021cites this paper
• Immune responses to human respiratory coronaviruses infection in mouse models

  2021cites this paper
• Potential impact of SARS-CoV-2 infection on the thymus.

  2020cites this paper
• Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

  2020cites this paper
• Factors Affecting SARS-CoV-2 (COVID-19) Pandemic, including Zoonotic, Human Transmission and Chain of Infection. Reducing Public Health Risk by Serum Antibody Testing, Avoiding Screening in Unhygienic Places and False PCR Reporting. A Scientific Review

  2020cites this paper
• Infectivity, virulence, pathogenicity, host-pathogen interactions of SARS and SARS-CoV-2 in experimental animals: a systematic review

  2020cites this paper
• SARS-CoV-2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?

  2020cites this paper
• A perspective on potential antibody-dependent enhancement of SARS-CoV-2

  2020cites this paper
• Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaques

  2020cites this paper
• Evolution of immunity to SARS-CoV-2

  2020cites this paper
• Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability

  2020cites this paper
• Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2

  2020cites this paper
• Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19

  2020cites this paper
• Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

  2020cites this paper
• The Novel Coronavirus 2019 (COVID-19): A Narrative Review

  2020cites this paper
• Review of infective dose, routes of transmission, and outcome of COVID-19 caused by the SARS-COV2 virus: comparison with other respiratory viruses Running title: COVID-19 infective dose review

  2020cites this paper
• Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19

  2020cites this paper
• Lessons for COVID-19 Immunity from Other Coronavirus Infections

  2020cites this paper
• Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals

  2020cites this paper
• SARS-CoV-2 neutralizing antibody development strategies

  2020influential citation
• SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries

  2020cites this paper
• A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV

  2020cites this paper
• Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?

  2020cites this paper
• Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

  2020cites this paper
• Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 disease severity

  2020cites this paper
• Review of infective dose, routes of transmission and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses

  2020cites this paper
• Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection

  2020cites this paper
• Immune responses to SARS-CoV-2 in children of parents with symptomatic COVID-19

  2020cites this paper
• Approaches and Challenges in SARS-CoV-2 Vaccine Development

  2020cites this paper